CCR4 and neoplasm: Interestingly, the defucosylated anti‐CCR4 antibody mogamulizumab is approved for use in cutaneous T‐cell lymphoma and adult T‐cell leukemia/lymphoma, where it facilitates the removal of tumor cells through enhanced ADCC [30, 294].